Skip to main content
Caplight Logo









Mirugen

Mirugen

Private
MelbourneHealthcare & Life Scienceshttps://www.mirugen.com/

Last Round

Seed

Aug 14, 2025

Total Funding Raised

$4.55M

Company Overview

Mirugen is a biotechnology company developing gene therapy to treat blindness by reprogramming cells to unlock innate cellular repair mechanisms.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Application

Keywords

gene therapycellular reprogrammingvision restorationphotoreceptor regenerationretinitis pigmentosain-vivo reprogrammingregenerative medicinepreclinical biotechAAV gene therapycomputational biologyretinal regenerationage-related macular degenerationbioinformaticsdrug discovery platformStargardt's diseasetranscription factors

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Mirugen Comparables

Compare Mirugen with similar companies based on industry and business-model similarity.

Mirugen comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ray Therapeutics
78%
Life Biosciences
77%
SparingVision
76%

Mirugen Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedAug 14, 2025
GrantDec 23, 2024

Key People

Founding team and executive leadership

Raymond Wong

Founder Chief Scientific Officer

Founding Team

Mirugen Investors

Notable investors and investment history

Mirugen investors
InvestorRounds
CUREatorGrant
ANDHealthGrant
Brandon CapitalSeed
Tin Alley VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 14, 2025

    $3M round led by Brandon Capital, genesispsf, and Tin Alley Ventures.

  • Dec 23, 2024

    $1.27M grant round led by CUREator.

Recent news

Latest coverage and updates

  • is_developingJul 16, 2026

    Mirugen Pty Ltd is developing AAV-based gene therapy candidate targeting Retinitis Pigmentosa on Jul 17th '26.

Mirugen Filings

Explore SEC and related filing metadata, where available.

Mirugen filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Mirugen's valuation, stock price, and market status.

Is Mirugen a public or private company?

Mirugen is a private company.

What is the current stock price of Mirugen?

Mirugen is a private company with no public stock price. No recent secondary market data is available.

How much is Mirugen worth (valuation)?

Valuation information for Mirugen is not publicly available.

Can I buy Mirugen stock?

Mirugen shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Mirugen's last funding round?

Funding round information for Mirugen is not publicly available.

Who are the main investors in Mirugen?

Investor information for Mirugen is not publicly disclosed.

Will Mirugen IPO soon?

No public IPO plans have been announced for Mirugen.

How can I track Mirugen secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Mirugen's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMelbourne
Employee Range3
Year Founded2022
Last FundingAug 14, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?